176 Chapter 9 49. Ali Mohammed Alsamil. PhD thesis. Quality of biopharmaceuticals: Comparability exercise and postapproval surveillance. Chapter 1 General Introducton. 2022; 1; 11. 50. Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol. 2016; 21-22: 75-83. 51. Grimaldi C, Ibraghimov A, Kiessling A, Rattel B, Ji C, Fuller CL, Brennan FR, Regenass-Lechner F, Shenton J, Price KD, Piche MS, Steeves MA, Prell R, Dudal S, Kronenberg S, Freebern W, Blanset D. Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics. Drug Discov Today. 2022; 28: 103440. 52. Rudge SR, Ladisch MR. Industrial Challenges of Recombinant Proteins. Adv Biochem Eng Biotechnol. 2020; 171: 1-22. 53. Lee SY. Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine. Ann Lab Med. 2020; 40: 95-96. 54. Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019; 15: 837-848. 55. Perry M, Abdullah A, Frleta M, MacDonald J, McGucken A. The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2020; 12: 1759720X20904850. 56. NZA. Sluisgeneesmiddelen: Sluis voor dure geneesmiddelen. https://www.zorginstituutnederland.nl/ over-ons/programmas-en-samenwerkingsverbanden/horizonscan-geneesmiddelen/sluis-voor-duregeneesmiddelen. Accessed on 08-01-2023. 57. Aries AM, Bailey P, Hunter SM. The mutual benefits of patient and public involvement in research: an example from a feasibility study (MoTaStim-Foot). Res Involv Engagem. 2021; 7: 87. 58. van Balen EC, Wesselo ML, Baker BL, Westerman MJ, Coppens M, Smit C, Driessens MHE, Leebeek FWG, van der Bom JG, Gouw SC. Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. Patient. 2020; 13: 201-210. 59. Smit C. Personal reflections of a patient representative in an appraisal committee. Patient. 2015; 8: 5-10. 60. Kirwan JR, de Wit M, Frank L, Haywood KL, Salek S, Brace-McDonnell S, Lyddiatt A, Barbic SP, Alonso J, Guillemin F, Bartlett SJ. Emerging Guidelines for Patient Engagement in Research. Value Health. 2017; 20: 481-486. 61. Cheung PP, de Wit M, Bingham CO, 3rd, Kirwan JR, Leong A, March LM, Montie P, Scholte-Voshaar M, Gossec L. Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. J Rheumatol. 2016; 43: 187-193. 62. Cnossen MH, van Moort I, Reitsma SH, de Maat MPM, Schutgens REG, Urbanus RT, Lingsma HF, Mathot RAA, Gouw SC, Meijer K, Bredenoord AL, van der Graaf R, Fijnvandraat K, Meijer AB, van den Akker E, Bierings R, Eikenboom JCJ, van den Biggelaar M, de Haas M, Voorberg J, Leebeek FWG, consortium S. SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. J Thromb Haemost. 2022; 20: 2001-2011. 63. Bukkems LH, Fischer K, Kremer-Hovinga I, Donners AAM, Fijnvandraat K, Schutgens REG, Cnossen MH, Mathot RAA. Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. Thromb Haemost. 2022; 122: 208-215.
RkJQdWJsaXNoZXIy MTk4NDMw